Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New seizure therapy aims to curb suicidal thoughts with fewer side effects

NCT ID NCT06529029

Disease control Sponsor: Michigan State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study compares a new, lower-energy seizure therapy (LAP-ST) to standard electroconvulsive therapy (ECT) for quickly reducing suicidal thoughts in people with depression, bipolar disorder, or schizoaffective disorder. The goal is to see if the gentler approach works just as well but causes less memory loss. About 30 adults aged 18 to 90 will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Low Amplitude Pulse Seizure Therapy (LAP-ST) device
What this could lead to
If it works, this could offer a safer, more tolerable option for quickly reducing suicidal thoughts in people with severe depression or bipolar disorder.
What could go wrong
This is an early-stage trial with only 30 participants, so results may not apply to everyone. The therapy is still experimental and may not work as well as standard ECT.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients in whom ECT is clinically indicated: The referrals to ECT by the primary psychiatrist (before a consult by the ECT consultant) will serve to both increase the feasibility of the study and address any ethical concerns that the patient would not undergo ECT without having a valid full indication for the procedure as well as increase the external validity and generalizability of the study. 2. Male or female patients 18 to 90 years of age 3. Current DSM-5 criteria for MDE with any SI of major depressive, bipolar, or schizoaffective disorders 4. Montgomery-Asberg depression rating scale (MADRS) with 2 or more on SI item 5. Use of effective method of birth control for women of child-bearing capacity 6. Patient is medically stable 7. No anticipated need to alter psychotropic medications for the duration of the study (except for urgent/emergent situations) 8. Ability of patient to fully participate in the informed consent process Exclusion Criteria: 1. Unstable or serious medical condition that substantially increases risks of ECT or cognitive impairment 2. Female patients who are pregnant or plan to be pregnant during the study or are breast-feeding 3. History of neurological disorder if deemed by the treating ECT physician or PI to pose a significant risk with ECT, or if there is any metal in the head or history of known structural brain lesion or skull defect that is deemed to affect cognition or safe ECT treatment 4. Implanted devices that make ECT unsafe 5. Clinical presentation of delirium or dementia 6. Active substance use disorders within 1 week of randomization 7. ECT in the past 1 month or prior failure to respond to an adequate course of ECT as deemed by the ECT physician treating the patient or the PI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bipolar disorder Depression major depressive disorder Psychotic Disorders schizoaffective disorder Suicidal Ideation Suicide

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bipolar disorder Major depressive disorder Schizo affective disorder Suicidal ideation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pine Rest Christian Mental Health Services

    RECRUITING

    Grand Rapids, Michigan, 49548, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.